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Accepted 17 December 2012Pyoderma gangrenosum (PG) is an acute inﬂammatory process
of the skin, also referred to as sterile neutrophil dermatosis
because of observations of skin ulceration with neutrophil inﬁl-
tration during histopathological examination [1]. The gross
appearance of PG includes bullae, pustules, erosion, and deep ul-
ceration with suppurative discharge or necrosis [2]. Although
some systemic diseases can induce PG, its exact cause and etiology
remain unclear [3]. It is considered an autoimmune-mediated
neutrophilic vasculitis that develops after skin trauma [4]. Ste-
roid and immunosuppressive therapies are typically the most
effective treatments for PG [1].
Vulvar PG is extreme rare and easily misdiagnosed as a sexually
transmitted disease or vulvar malignancy. Genital skin defects
typically fail to heal because of ease of contamination. Patients
often experience local hygiene problems and psychological stress.
In this study, we present a case of bilateral vulvar extensive PG,
which showed rapid recovery following aggressive debridement
and systemic steroid treatment.
A 60-year-old para 2 menopausal Taiwanese woman reported
experiencing persistent vulvar discomfort for 1.5 months. A pruritic
pustule in her right labium majora had developed into two deep
and painful ulcerative wounds in both labia majora, with a sharp
and elevated border covered with granulation tissue. The use of
topical therapy had not improved her condition before referral.
The patient’s general gynecological and surgical history had not
contributed to her condition. Her menopausal age was 50 years
old and she had not received any hormonal therapy. She had hadConﬂicts of interest: The authors have no conﬂicts of interest to declare.
* Corresponding author. Division of Gynecologic Oncology, Department of Ob-
stetrics and Gynecology, Mackay Memorial Hospital, Number 92, Section 2, Chung-
Shan North Road, Taipei 10449, Taiwan.
E-mail address: cremaster4471@gmail.com (J.-R. Chen).
http://dx.doi.org/10.1016/j.tjog.2012.12.006
1028-4559/Copyright  2014, Taiwan Association of Obstetrics & Gynecology. Publishedno sexual intercourse for 10 years following the onset of meno-
pause. No systemic symptoms, such as joint pain, redness of the
eyes, oral ulcers, hematochezia, or diarrhea, were noted. Pelvic
examination revealed a deep ulceration with a purulent discharge
coating in the right labium majora. It measured approximately
10 cm  3 cm, extending from the right monk of the pubis to the
perineal area. A small superﬁcial skin erosion, measuring
approximately 2 cm  2 cm, was also located in the left labium
majora (Fig. 1). The vaginal mucosa, anus, and cervix were grossly
normal. Bimanual examination revealed typically sized uterine
and bilateral adnexa. The bilateral inguinal lymph nodes were not
palpable.
The results from a series of laboratory studies, including routine
blood tests, squamous cell carcinoma antigen (tumor marker), and
syphilis tests, were all within reference ranges. Culture of local
purulent discharge did not reveal any bacterial growth. Biopsy of
the lesion was not conducted because of the patient’s personal
decision. A computed tomography scan of the pelvis extending to
the inguinal area, cystoscopy, and colonoscopy all provided unre-
markable ﬁndings. Limited improvement was shown following
conservative treatment using a topical cream containing grami-
cidin, neomycin, nystatin, and triamcinolone (Mycomb cream;
Sinphar Pharmaceutical, Taipei, Taiwan).
After patient counseling, surgical debridement and reconstruc-
tion of the deep skin defects were conducted following colonic
preparation. The unviable necrotic skin and granulation tissuewere
superﬁcially excised. Primary repair without ﬂap reconstruction
was performed (Fig. 2). Histopathological studies revealed mixed
acute and chronic inﬂammation, granulation tissue formation, and
adjacent epithelial hyperplasia. Tissue with neutrophil inﬁltration
was compatible with the diagnosis of PG, the same as benign
chronic neutrophilic dermatosis.
For treatment of PG, postoperative therapeutic goals are wound
care and the provision of systemic immunosuppressive therapy.
Steroids are helpful in preventing the recurrence of PG close to the
surgical area (pathergy phenomenon; Wegener’s granulomatosis).
First, 100 mg hydrocortisol was injected intravenously every 6
hours for 3 days. Oral dexamethasone treatment was thenby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Pyoderma gangrenosum of the bilateral vulva. The right side ulceration
measured approximately 10 cm  3 cm (red arrow head), extending from the monk of
the pubis to the perineal area. The left side superﬁcial skin erosion measured
2 cm  2 cm (blue arrow head), located in the labium majora only.
Fig. 3. Twenty-one days after surgery, the patient showed cosmetic recovery with no
ulcer recurrence (no pathergy phenomenon).
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an uneventful postoperative course, showing good wound healing
and cosmetic recovery within 3 weeks of surgery (Fig. 3). Oral
dexamethasone treatment was ceased 3months after surgery using
a gradual tapering schedule. The patient remains no local
recurrence.Fig. 2. Surgical debridement and primary repair of the vulvar lesion.PG is a rare dermatological aseptic neutrophil-inﬁltrated cuta-
neous destructive disease. It has an estimated incidence of 3e10
cases per million people/year [5]. The primary affected group is
women of reproductive age [6]. In 1996, Powell et al clinically
classiﬁed PG into four subgroups: ulcerative, pustular, bullous, and
vegetative types [2]. The most common subgroup is the ulcerative
type (>80%), and the most frequently affected sites are the legs,
trunk, upper limbs, and head and neck region [6]. Symptoms of PG
include painful enlarging necrotic ulcers with bluish undermined
borders surrounded by advancing zones of erythema [7].
Vulvar PG is extremely rare, predominantly occurring in pedi-
atric patients, and reported only in case reports. The cases reported
worldwide are summarized in Table 1. A diagnosis of vulvar PG is
made by exclusion. Physicians need to exclude venereal vulvar ulcer
(a sexually transmitted disease, such as chancre or chancroid),
premalignancy, malignancy (primary vulvar carcinoma), non-
venereal vulvar ulcer (Behçet’s disease or Crohn’s disease), and
traumatic and factitial ulceration before conﬁrming vulvar PG [8].
Because of its rarity, the mechanism underlying PG remains
unclear. However, it is believed to be associated with immune-
mediated dysfunction or autoimmune reaction [6]. Although
most cases are idiopathic, PG is often associated with other sys-
temic diseases, such as Crohn’s disease, ulcerative colitis, rheuma-
tological disease, and hematological malignancy [9]. Occasionally,
PG develops after surgery without any known etiology. Recently,
Wollina et al associated PG with pyogenic arthritis, pyoderma
gangrenosum, and acne syndrome (PAPA syndrome), an autosomal
dominant hereditary disease [7]. A case series by Binus et al further
associated hepatitis C infection with PG [6].
Treatment of PG is challenging. Systemic steroid treatment rep-
resents themost acceptable and effective therapy for acute stage PG;
Table 1
Systematic summary and literature review of vulvar PG.
Author Year Age Associated disease Treatment of vulvar PG Refs
Chen et al 2012/2013 67 None Surgical debridement and systemic
steroid, hydrocortisol 100 mg every 6 h
This article
Marzano et al 2012 37 Renal involvement Systemic steroid Eur J Dermatol. 2012;22:537e9.
(case report)
Browning et al 2011 10 None Systemic steroid prednisone 1 mg/kg/d Child Abuse Negl. 2011;35:230e3
(case report)
Walsh et al 2011 51 Non-Hodgkin’s
lymphoma with
rituximab therapy
Systemic steroid prednisolone 1 mg/kg/d
and minocycline 200 mg/d
J Low Genit Tract Dis. 2011;15:158e60.
(case report)
Garcovich et al 2009 10 None Systemic steroid methylprednisolone
30 mg/d, cyclosporine A 3.2 mg/kg/d
Pediatr Dermatol. 2009;26:629e31.
(case report)
Matsuo et al 2009 48 and 37 Vulvar mucinous
adenocarcinoma
Surgery and chemotherapy
(5-ﬂuorouracl, oxaliplatin, bevacizumab)
Gynecol Obstet Invest. 2009;68:276e8.
(case report, 2 cases)
Leu et al 2009 43, 25 and 52 Crohn’s disease Systemic steroid, 6-mercaptopurine
(1st case), oral budesonide and
azathioprine (2nd case), adalimumab
(3rd case)
Dig Dis Sci. 2009;54:1565e71.
(case report, 3 cases)
Sripathi et al 2008 48 Recurrence vulvar PG Systemic steroid and dapsone Indian J Dermatol Venereol
Leprol. 2008;74:506e8.
(case report)
Roé et al 2006 44 Collagenous colitis Cyclosporine 3 mg/kg/d BID Topical
tacrolimus 0.1% locally
Dermatology. 2006;213:234e5.
(case report)
Langeland et al 2004 55 None Cyclosporin A, 5 mg/kg/d Acta Obstet Gynecol Scand.
2004;83:1220e1. (case report)
Valmadre et al 2002 19 None Systemic steroid, prednisolone 30 mg Aust N Z J Obstet Gynaecol.
2002;42:548e9. (case report)
Sau et al 2001 73 Pulmonary tuberculosis Systemic steroid prednisolone 50 mg/d
and minocycline 100 mg BID
BJOG. 2001;108:1197e8.
(case report)
Borum et al 1998 44 Crohn’s disease Systemic steroid and azulﬁdine (initially),
Azathioprine , Cyclophosphamide, plaquenil,
minocycline, and thalidomide (recurrence)
Dig Dis Sci. 1998;43:720e2.
(Letter to editor)
Lebbé et al 1992 58 Lung involvement Systemic steroid, prednisolone 1 mg/kg/d J Am Acad Dermatol. 1992;27:623e5.
(case report)
McCalmont et al 1991 29 None Systemic steroid, Prednisolone 80 mg/d Int J Gynaecol Obstet. 1991;35:175e8.
(2nd case report in gynecological
literature)
Grant et al 1989 66 and 76 Leukemia (AML, 1st case),
rheumatoid arthritis
(2nd case)
No therapy (1st case), surgery (2nd case),
both expired
Aust N Z J Obstet Gynaecol. 1989;
29:360e2. (2 cases)
Segal et al 1979 N/A Crohn’s disease and
sclerosing cholangitis
N/A S Afr Med J. 1979;7;55:596e9.
(case report)
Chachaj et al 1977 N/A Ulcerative colitis N/A Wiad Lek. 1977;1;30:715e8.
(case report)
BID ¼ twice daily; N/A ¼ not available; PG ¼ pyoderma gangrenosum.
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rheumatological therapies, such as immunosuppressants, immu-
nomodulatory agents, anti-inﬂammatory drugs, cytotoxic drugs,
interleukin-1, and tumor necrosis factor-a inhibitor or its antago-
nists, are all reportedly effectivewhen administered in combination
with traditional steroid treatment [1]. Leukocytapheresis can also
removeactiveneutrophils in theblood to treatunresponsivePG [10].
Debridement of necrotic tissue for PG is not usually recom-
mended because the surgical procedure might trigger an immune
system response. Reported cases of surgical debridement and split
skin grafts for PG lesions have generally had poor outcomes. As a
result of the pathergy phenomenon, additional ulceration and ne-
crosis in traumatic wound areas or skin ﬂaps is probable. However,
a case series study identiﬁed that w30% of patients who had un-
dergone gentle sharp debridement and active wound management
through skin graft or reconstruction showed successful disease
remission [6]. A Korean study further described that surgical
intervention following immunosuppressant stabilization can
accelerate the PG healing course [11]. According to a case report by
Vieira et al, hyperbaric oxygen therapy improves the surgical
outcome of PG [12].
Vulvar or genital PG causes local hygiene problems, irritation
during urination and defecation, and secondary infection inaffected skin areas receiving traditional medical treatment. In our
reported case, surgical intervention, including debridement of
nonviable tissue and local reconstruction, provided three main
beneﬁts: acceleration of ulcer healing when combined with sys-
temic therapy; provision of a specimen for histopathological ex-
amination to exclude other underlying etiologies or malignancy of
the skin defect; and cosmetic improvement.
In conclusion, vulvar PG is extremely rare and requires speciﬁc
management. In our reported case, accurate diagnosis, opportune
systemic steroid treatment, and surgical intervention reduced the
patient’s comorbidity and accelerated her healing course without
any complications.References
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